Adavosertib - AstraZeneca
Alternative Names: AZD-1775; L001739996-008U; MK-1775; MK-1775 hemihydrateLatest Information Update: 13 Jul 2024
At a glance
- Originator Merck & Co
- Developer AstraZeneca; Canadian Cancer Trials Group; Cancer Research UK; Dana-Farber Cancer Institute; Merck & Co; National Cancer Institute (USA); Samsung Medical Center; University of Birmingham; University of Texas M. D. Anderson Cancer Center; University of Washington
- Class Aniline compounds; Antineoplastics; Piperazines; Pyrazoles; Pyridines; Pyrimidinones; Small molecules
- Mechanism of Action WEE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cervical cancer; Colorectal cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Haematological disorders; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Uterine cancer; Vulvovaginal cancer
Most Recent Events
- 31 May 2024 Adverse events and efficacy data from a phase-II trial in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 May 2024 Discontinued - Phase-I for Glioblastoma (Recurrent, Newly diagnosed, Combination therapy) in USA (PO)
- 28 May 2024 Discontinued - Phase-I for Haematological disorders (Combination therapy, First-line therapy, Second-line therapy or greater) in USA (PO)